ClinicalTrials.gov
public full text
Public Domain
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol#1085795
- The International Nocturnal Oxygen (INOX) Trial#1173611
- Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)#902824
- Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD#905902
- Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease in General Practice#1173640
Record · ID 1100803
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive